TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 778998
Drug: Piribedil in
Normalized name: piribedil Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil in association with L‐Dopa
Study: 29756308
Drug: Oral Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Group (OG)
Study: 24628390
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d folate supplements
Study: 18570896
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii treatment
Study: 11251331
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enoxaparin administered subcutaneously
Study: 1855737
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg twice daily for 1 year)
Study: 31826368
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (3.4 g) combined with muscle strengthening exercises
Study: 31826368
Drug: Control (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1.2 g of starch)
Study: 26959879
Drug: Flurbiprofen (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (administered before skin incision and at the end of operation), n=30
Study: 17394653
Drug: Pretreatment intervention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment intervention designed to enhance treatment motivation, decrease crack use, and prepare for treatment entry.
Study: 8558187
Drug: VM26 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM26 120 mg/m2 on days 1, 3, and 5 with cisplatin 80 mg/m2 on day 1
Study: 8558187
Drug: VM26 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM26 360 mg/m2 on day 1 with cisplatin 80 mg/m2 on day 1
Study: 8558187
Drug: VM26 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM26 120 mg/m2 on days 1, 3, and 5 without cisplatin
Study: 8558187
Drug: VM26 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM26 360 mg/m2 on day 1 without cisplatin
Study: 1816217
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micrograms thrice daily
Study: 30294826
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health therapist intervention (OHTI)
Study: 25557228
Drug: Methylprednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (2 mg·kg(‐1))
Study: 24424704
Drug: ZST 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZST 1.75 mg
Study: 24424704
Drug: ZST 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZST 3.5 mg
Study: 22947342
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education intervention including measuring daily salt content, estimating 24-hour salt intake, and cooking classes with less salt
Study: 4934047
Drug: Drug combinations
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combinations
Study: 3901821
Drug: Active therapies
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapies (Ciramadol and Morphine)
Study: 29317812
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily for 4 weeks
Study: 29317812
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg) once daily for 4 weeks
Study: 18675765
Drug: Face-to-face medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face medication consultation provided by a community pharmacy resident.
Study: 16438891
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving therapy (BCT)
Study: 2043493
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (10 mg/kg iv. loading dose + 7 hours continuous infusion) + lorazepam (2.5 mg x 4 po)
Study: 2043493
Drug: Low-dose metoclopramide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoclopramide (70 mg) + lorazepam (2.5 mg x 2 po) + dehydrobenzperidol (5 mg x 2 im)
Study: 30626198
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and other drug (AOD) use
Study: 30816108
Drug: Apatinib (VEGFR2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (VEGFR2 inhibitor)
Study: 30535668
Drug: Steroid arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid arm (methylprednisone)
Study: 25245572
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei subsp. paracasei L. casei W8 (1010 cfu)
Study: 16361302
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo capsules)
Study: 17094103
Drug: Entacapone 100
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entacapone 100 mg
Study: 12060504
Drug: 1% penciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% penciclovir cream
Study: 12060504
Drug: 3% aciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% aciclovir cream
Study: 9857648
Drug: Chemotherapy (mitomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (mitomycin, cisplatin, vinblastine)
Study: 2225705
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg once a day)
Study: 2225705
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 40 mg once a day)
Study: 552658
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg RG 033
Study: 552658
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg RG 033
Study: 30666357
Drug: LDH ≥
Normalized name: Lactate dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH ≥ 618 IU/L
Study: 28394172
Drug: Shorter total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter total wake time (TWT) before treatment session
Study: 28394172
Drug: Shorter total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter total wake time (TWT) after treatment session
Study: 28394172
Drug: Shorter total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter total sleep time (TST) before treatment session
Study: 28394172
Drug: Shorter total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter total sleep time (TST) after treatment session
Study: 23430381
Drug: 1.5 L
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 L PEG‐electrolyte solution plus 15 mg of mosapride
Study: 23430381
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐electrolyte solution plus 15 mg of mosapride
Study: 16934044
Drug: 8-prenylnaringenin (8-PN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-prenylnaringenin (8-PN) 750 mg
Study: 21839654
Drug: Percutaneous transluminal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy (immediate treatment group - ITG)
Study: 21839654
Drug: Percutaneous transluminal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous transluminal angioplasty (PTA) after 6 months of medical therapy alone (delayed treatment group - DTG)
Study: 21839654
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance imaging (MRI) results in immediate treatment group (ITG)
Study: 21839654
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance imaging (MRI) results in delayed treatment group (DTG)
Study: 16264053
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (Continuous Positive Airway Pressure)
Study: 7826293
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (insulin administration at least three times a day, adjusted based on self-blood glucose monitoring, aiming for normoglycemia)
Study: 7826293
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (one or two daily insulin injections)
Study: 305522
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Biarison
Study: 305522
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indometacin
Study: 305522
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Biarison (under double blind conditions)
Study: 30055303
Drug: DNS-7801 solutions
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNS-7801 solutions
Study: 30055303
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of citrate buffer at pH 3.0 and hydroxypropylbetadex
Study: 18402630
Drug: Lamotrigine treatment
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine treatment for 8 weeks
Study: 24796044
Drug: Jingjin acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingjin acupuncture treatment (including acupuncture on palm side of affected hand, dorsal metacarpophalangeal joints, and proximal interphalangeal joints, once every other day, with electroacupuncture when qi was acquired)
Study: 24796044
Drug: Jingjin acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingjin acupuncture treatment
Study: 20384388
Drug: DRSP 3
Normalized name: DRSP
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DRSP 3 mg/EE 30 microg
Study: 12427152
Drug: Oral l‐folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral l‐folinic acid at 20 mg/day
Study: 12427152
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid at 15 mg/day
Study: 30033514
Drug: Spirulina supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplement (2 g/day) plus conventional regimen (220 mg/day zinc sulfate, 500 mg/day L-carnitine, and 50 mg/day clomiphene)
Study: 26956541
Drug: Acupuncture (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (10 treatments over 8 weeks)
Study: 26956541
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (7 sessions over 8 weeks)
Study: 24132248
Drug: Galantamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (up to 24 mg/day)
Study: 22045595
Drug: TAS-108 40
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 40 mg daily
Study: 22045595
Drug: TAS-108 80
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 80 mg daily
Study: 22045595
Drug: TAS-108 120
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 120 mg daily
Study: 19308365
Drug: C/P (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/P (60 mg codeine + 1000 mg paracetamol) four times daily
Study: 19308365
Drug: L+C/P (levomepromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+C/P (levomepromazine 5 + 5 + 5 + 10 mg + C/P) four times daily
Study: 17259517
Drug: Thiazolidinediones (TZDs)
Normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones (TZDs) therapy
Study: 7515387
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg nightly for 6 months)
Study: 26472406
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Ozurdex and macular laser therapy (MLT)
Study: 26472406
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Ozurdex and MLT
Study: 23516656
Drug: Integrated control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated control strategy including praziquantel chemotherapy, controlling snails, building fences for bovines, safe pastures, and improving health conditions in six intervention villages.
Study: 23516656
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with routine interventions including praziquantel chemotherapy and controlling snails, without new interventions.
Study: 19033012
Drug: Zofenopril (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (30 mg/d)
Study: 9848785
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/d)
Study: 8760738
Drug: Combined Antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Antibiotic Groups (Amoxycillin and Penicillin V)
Study: 1313765
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg day-1 for three days)
Study: 1313765
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg kg-1 body weight for five days)
Study: 3860511
Drug: 0.02% stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% stannous fluoride (SnF2) solution using Water Pik
Study: 30422367
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone in combination with Botulinum Toxin A (BTA)
Study: 24286443
Drug: High-cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cocoa flavanol (CF) intervention (375 mg CF, HiFI)
Study: 24286443
Drug: Low-cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cocoa flavanol control (9 mg CF, LoFl)
Study: 22464260
Drug: MitraClip device
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip device treatment
Study: 20158897
Drug: Cognitive patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive patient education intervention (up to four weekly sessions, each lasting 30 minutes)
Study: 20158897
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment (control group)
Study: 16231532
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of gadolinium (0.2 mmol/kg)
Study: 16231532
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of gadolinium (0.1 mmol/kg)
Study: 12669122
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (group A)
Study: 11877267
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily low‐molecular‐weight heparin (reviparin) for 1 week (group B)
Study: 11877267
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily reviparin for 4 weeks (group C)
Study: 7542589
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine from nasal spray
Study: 7542589
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine from nasal spray with xylometazoline
Study: 401827
Drug: Disodium ethane‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 0, 2.5, 5, 10, or 20 mg/kg/day (randomized)
Study: 401827
Drug: Disodium ethane‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 10 or 20 mg/kg/day (non-randomized)
Study: 401827
Drug: Disodium ethane‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at 5 mg/kg/day
Study: 401827
Drug: Disodium ethane‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (various doses)
Study: 401827
Drug: Disodium ethane‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (higher doses)
Study: 23548119
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine use
Study: 16926256
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor letrozole
Study: 10942143
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of botulinum toxin (BOTOX) at a dosage of 2.5-U
Study: 10942143
Drug: Unilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral injection of botulinum toxin (BOTOX) at a dosage of 15-U
Study: 10942143
Drug: Bilateral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral and unilateral injections of botulinum toxin (BOTOX)
Study: 3536529
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg once daily
Study: 3536529
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg three times daily
Study: 3536529
Drug: Postponing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postponing the third dose until 10 p.m.
Study: 2901266
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 to 40 mg once daily
Study: 2901266
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 to 160 mg twice daily
Study: 25313847
Drug: Higher number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher number of prior PNS implants performed (NPPIP)
Study: 18061828
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amphotericin B (2.5 g) and itraconazole (6 months)
Study: 16836557
Drug: Perioperative iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative iron sucrose (2 x 200 mg/48 hr, IV) plus preoperative erythropoietin (EPO; 1 x 40,000 UI, sc) for patients with preoperative Hb < 130 g/L (Group A)
Study: 16836557
Drug: Postoperative unwashed
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative unwashed shed blood (USB) for patients with preoperative Hb < 130 g/L (Group B)
Study: 12569270
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (17 beta‐estradiol, 100 microg/24 h)
Study: 10863568
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (newsletters with and without telephone interviews)
Study: 1777372
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 or 100 mg once daily)
Study: 9114765
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 or 20 mg once daily)
Study: 30026341
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus arsenic
Study: 27423645
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with stem cell rescue (HDSCR)
Study: 27423645
Drug: Exploration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploration of new drugs
Study: 18457472
Drug: Bazedoxifene (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (10, 20 and 40 mg)
Study: 12424044
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine in 20 ml normal saline (Group B)
Study: 12424044
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg morphine in 20 ml normal saline (Group C)
Study: 12424044
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline (Group A)
Study: 2186991
Drug: Pirbuterol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol administered via the Autohaler
Study: 2186991
Drug: Salbutamol administered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol administered via the Diskhaler
Study: 6798902
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium cromoglycate
Study: 31120601
Drug: De-escalated radiation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalated radiation therapy (<66 Gy)
Study: 31120601
Drug: Full-dose radiation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose radiation therapy (≥66 Gy)
Study: 25409738
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g by intravenous injection followed by 3 g intravenous infusion over 24 hours)
Study: 22772170
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (2-dose regimen at a 1-month interval)
Study: 20142523
Drug: Latrepirdine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latrepirdine, 20 mg 3 times daily (n = 46)
Study: 17477888
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg/d (with dose adjustment to 50 mg/d if insufficient improvement)
Study: 17222829
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg/d)